Top 6 Companies Viral Vector and Plasmid DNA Manufacturing Market

Market Overview:

The Global Viral Vector and Plasmid DNA Manufacturing Market is estimated to be valued at USD 601.8 Million in 2021 and to attain a value of USD 1902.7 Million by 2028 at a CAGR of 16.1% during the forecast period, 2022-2028. The need for viral vector-based vaccination for infectious diseases is increasing with the current shift in the treatment paradigm of various life-threatening diseases through sophisticated therapeutics. As a result, more viral vector and plasmid DNA constructs are being used in R&D of new drugs, spurring the market for viral vector and plasmid DNA constructs.

Furthermore, the COVID-19 pandemic has offered profitable prospects for the market participants. For example, in December 2020 and February 2021, multinational pharmaceutical companies such as AstraZeneca and Janssen Pharmaceuticals developed COVID-19 viral vector-based vaccines, respectively. In addition to these firms, several viral vector-based vaccines are now in development. As a result, the demand for viral vectors has increased, resulting in increased revenue for viral vector manufacturers.

Following are the top 6 leading companies in the Global Viral Vector and Plasmid DNA Manufacturing Market:

• Fujifilm Diosynth Biotechnologies
• SIRION Biotech
• Thermo Fisher Scientific
• Merck KGaA Inc.
• Cognate BioServices Inc.
• Cobra Biologics

Fujifilm Diosynth Biotechnologies

The company began with the extraction of insulin from bovine pancreas in Oss, Netherlands in 1923 and the extraction of porcine insulin in 1930, both of which are still part of their main products. January 2005. In 2006, the company became a part of Organon, one of its subsidiaries in the Akzo Nobel Pharma group. In March 2007 Akzo Nobel sold Organon and Intervet, along with its subsidiaries, to Schering-Plough. Following Schering-Plow's merger with Merck & Company (MSD) on March 9, 2009, the company was part of the MSD Nutritional Products Company, which belonged to the MSD Group. In April 2011, the company was sold to Fujifilm and formed Fujifilm Diosynth Biotechnologies. On December 18, 2014, Fujifilm Diosynth Biotechnologies acquired Kalon Biotherapeutic Technologies in College Station, TX, which became Fujifilm Diosynth Biotechnologies Texas, LLC.

SIRION Biotech

SIRION Biotech was established in 2005 with the goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccine development. SIRION evolves novel therapeutic viral vectors and uses proprietary technology platforms based on lenti-, adeno-, and adeno-associated viruses to expedite its partners’ advances in drug development. The company is easily accessible with headquarters in Munich, as well as offices and agents in Boston, Paris, Tokyo, Seoul, and Tel Aviv.

Thermo Fisher Scientific

Thermo Fisher Scientific is an American supplier of scientific equipment, reagents and consumables, and software services. Based in Waltham, Massachusetts, Thermo Fisher was formed in 2006 through the merger of Thermo Electron and Fisher Scientific. Thermo Fisher has acquired other reagent, consumable, instrumentation and service providers, including: Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016),  FEI Company. (2016), and BD Advanced Bioprocessing (2018).

As of 2017, the company had a market capitalization of $21 billion and was a Fortune 500 company. As of 2018, the company employed on the order of 70,000 employees and was reporting US$24 billion in annual revenue.

In March 2020, Thermo Fisher received emergency use authorization from the FDA to test for SARS-CoV-2 to help ease the COVID-19 pandemic.

Merck KGaA Inc.

Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with approximately 57,000 employees and present in 66 countries. The group comprises about 250 companies; The main company is Merck KZA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the oldest operating chemical and pharmaceutical company in the world, as well as one of the largest pharmaceutical companies in the world. Merck operates in Europe, Africa, Asia, Oceania and the Americas. It has major research and development centers in Darmstadt, Boston, Tokyo and Beijing, as well as other research and development units in Taiwan, France, Israel, South Korea, India and the UK.

Cognate BioServices Inc.

Established in 1992 based in Baltimore, Maryland Cognate provides a unique combination of custom development and cGMP manufacturing services to companies across all types of autologous and allogeneic clinical and commercial cell and gene therapy applications. The organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies, organizations and institutions.

Cobra Biologics

Established in 1992 Headquarters  in Keele, Stoke-on-Trent, United Kingdom COBRA provides a comprehensive Biologics and Pharmaceuticals service offering with multi-functional and experienced Advanced Therapeutics project teams, manufacturing clients' plasmid DNA and viral vector products from pre-clinical to clinical and commercial manufacturing within GMP approved facilities.

Get Sample Report Here: https://www.vantagemarketresearch.com/viral-vector-and-plasmid-dna-manufacturing-market-1303/request-sample

For More Information about each of these companies.  

Vantage Market Research Report comes up with detail analysis of each major player in the industry

The Study provides Global market size& share, Emerging trends, In-depth analysis of key players, Development opportunities, Sales, Revenue Forecast.